| Original language | English (US) |
|---|---|
| Pages (from-to) | 797-800 |
| Number of pages | 4 |
| Journal | Expert review of cardiovascular therapy |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2011 |
Bibliographical note
Funding Information:Ali A Sovari is funded by the American Heart Association Midwest Affiliate Postdoctoral Fellowship Award (grant no. AHAA10POST4450037). Samuel C Dudley is funded by the National Institute of Health (grant no. RO1 RO1HL085558, PO1 HL058000). Samuel C Dudley has the following pending patents: Prevention of sudden death by modulation of Src family (application no. 13/032,629); Modulating mitochondrial reactive oxygen species to increase cardiac sodium current and mitigate sudden death (application no. CIP 12/929786); Oxidative stress markers predict atrial fibrillation (application no. 11/882,627). Ali A Sovari and Samuel C Dudley have the pending patent: Mitochondria anti-oxidants for prevention of sudden death by raising connexin43 levels (application no. 61/503,096). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antiarrhythmic
- arrhythmia
- atrial fibrillation
- oxidative stress
- sudden cardiac death
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS